Kim C. M. van der Elst

Quantification of Upadacitinib, Dasatinib, Ruxolitinib, Imatinib, and Cabozantinib in Plasma With Liquid Chromatography-Tandem Mass Spectrometry.

BACKGROUND Tyrosine kinase inhibitors (TKIs) are increasingly used to treat hematological malignancies and solid tumors. As pharmacokinetic variability is substantial among patients, therapeutic drug monitoring may help optimize treatment efficacy and minimize toxicity. However, simultaneous quantification of multiple...